Peter Johnson
Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma
Araf S, Fitzgibbon J, Okosun J, Johnson P, Davies A, Rimsza L, Scott D, Graham T, Barrington S, Forrer F, Kumar E, Cogliatti S, Wang J, Bewicke-Copley F, Korfi K, Fehr M. Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma. Haematologica 2020; 105:318-321.
09.04.2020Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma
09.04.2020Haematologica 2020; 105:318-321
Araf Shamzah, Fitzgibbon Jude, Okosun Jessica, Johnson Peter, Davies Andrew, Rimsza Lisa M, Scott David W, Graham Trevor A, Barrington Sally F, Forrer Flavio, Kumar Emil, Cogliatti Sergio B., Wang Jun, Bewicke-Copley Findlay, Korfi Koorosh, Fehr Martin
Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98)
Lee C, Ashton-Key M, Cogliatti S, Rondeau S, Schmitz S, Ghielmini M, Cragg M, Johnson P. Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98). Br J Haematol 2014; 168:145-8.
21.08.2014Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98)
21.08.2014Br J Haematol 2014; 168:145-8
Lee Chern Siang, Ashton-Key Margaret, Cogliatti Sergio B., Rondeau Stephanie, Schmitz Shu-Fang Hsu, Ghielmini Michele, Cragg Mark S, Johnson Peter
Mechanism of action of rituximab
Cerny T, Borisch B, Introna M, Johnson P, Rose A. Mechanism of action of rituximab. Anti-cancer drugs 2002; 13 Suppl 2:S3-10.
01.11.2002Mechanism of action of rituximab
01.11.2002Anti-cancer drugs 2002; 13 Suppl 2:S3-10
Cerny Thomas, Borisch Bettina, Introna Martino, Johnson Peter, Rose Andrea L